Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer

摘要: Lung cancer is the leading cause of cancer-related mortality in both men and women approximately 219,440 new cases nonsmall cell lung (NSCLC) were estimated to occur USA 2009, which caused 159,390 NSCLC-related deaths. More than 50% advanced NSCLC are diagnosed patients older age 65, recent Surveillance Epidemiology End Results (SEERs) data suggest that median at diagnosis 70 years. Until recently, disease has been undertreated this patient population, with a perception among many clinicians elderly do not tolerate chemotherapy or radiotherapy. So, single agent recommended approach by ASCO International Expert Panels unselected patients. The introduction novel targeted therapies, such as Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) improved survival versus placebo who had previously failed on chemotherapy, gives new, effective, better tolerated options consider when treating This paper describes advances EGFR TKIs for NSCLC.